189 related articles for article (PubMed ID: 2970555)
1. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.
Canney PA; Priestman TJ; Griffiths T; Latief TN; Mould JJ; Spooner D
J Natl Cancer Inst; 1988 Sep; 80(14):1147-51. PubMed ID: 2970555
[TBL] [Abstract][Full Text] [Related]
2. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.
Petru E; Schmähl D
Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170
[TBL] [Abstract][Full Text] [Related]
3. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
4. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
5. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
[TBL] [Abstract][Full Text] [Related]
6. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Garcia-Giralt E; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A; Guerin D; Guerin R
Breast Cancer Res Treat; 1992; 24(2):139-45. PubMed ID: 8443401
[TBL] [Abstract][Full Text] [Related]
7. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone.
Alberto P; Mermillod B; Kaplan E; Goldhirsch A; Obrecht JP; Jungi F; Martz G; Barrelet L; Cavalli F
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):423-8. PubMed ID: 3891359
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer.
Samonis G; Margioris AN; Bafaloukos D; Razis DV
Oncology; 1994; 51(5):411-5. PubMed ID: 8052481
[TBL] [Abstract][Full Text] [Related]
9. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA
Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938
[No Abstract] [Full Text] [Related]
10. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.
Halpenny O; Bye A; Cranny A; Feely J; Daly PA
Med Oncol Tumor Pharmacother; 1990; 7(4):241-7. PubMed ID: 2149401
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P
Oncology; 1988; 45(5):350-3. PubMed ID: 3045726
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
13. Additive hormonal therapy in women with advanced breast cancer.
Ingle JN
Cancer; 1984 Feb; 53(3 Suppl):766-77. PubMed ID: 6229323
[TBL] [Abstract][Full Text] [Related]
14. [Progestational agents and bone metastasis in breast cancer].
Leriche N; Bonneterre J
Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone.
Quinn MA; Campbell JJ; Murray R; Pepperell RJ
Aust N Z J Obstet Gynaecol; 1981 Nov; 21(4):226-9. PubMed ID: 6951563
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen therapy of metastatic breast cancer.
Manni A
J Lab Clin Med; 1987 Mar; 109(3):290-9. PubMed ID: 2950193
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal control of disseminated breast cancer].
Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
Sov Med; 1990; (6):94-7. PubMed ID: 2144368
[No Abstract] [Full Text] [Related]
19. [Which hormone therapy should be used in advanced breast carcinoma in males?].
Lönning PE; Wiedemann G; Kvinnsland S; Lundgren S
Dtsch Med Wochenschr; 1988 Sep; 113(35):1358-61. PubMed ID: 2970379
[TBL] [Abstract][Full Text] [Related]
20. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.
Izuo M; Yoshida M; Tominaga T; Abe O; Enomoto K; Nomura Y; Kubo K; Takatani O
Cancer; 1985 Dec; 56(11):2576-9. PubMed ID: 2932213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
